Rein Therapeutics, Inc. Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
Rein Therapeutics, Inc. (RNTX) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2026-08-14
- Rein Therapeutics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2026-06-30 was $0.00.
- Rein Therapeutics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2026-03-31 was $0.00.
- Rein Therapeutics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2025-12-31 was $28.70M, a 22.43% decline year-over-year.
- Rein Therapeutics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2025-09-30 was $0.00.
- Rein Therapeutics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2024 was $37.00M.
- Rein Therapeutics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2023 was $0.00.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 3 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 6 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 9 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-14 | $0.00 10-Q · filed 2026-08-14 | $28.70M derived: sum of 3 quarters · filed 2026-08-14 | $28.70M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-15 | $28.70M derived: sum of 2 quarters · filed 2026-08-14 | $28.70M derived: sum of 3 quarters · filed 2026-08-14 | $28.70M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $28.70M derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-14 | $28.70M derived: sum of 2 quarters · filed 2026-08-14 | $28.70M derived: sum of 3 quarters · filed 2026-08-14 | $28.70M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2025-11-14 | $0.00 10-Q · filed 2025-11-14 | $37.00M derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 | $37.00M derived: sum of 3 quarters · filed 2026-03-26 | $37.00M derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-15 | $37.00M derived: sum of 2 quarters · filed 2026-03-26 | $37.00M derived: sum of 3 quarters · filed 2026-03-26 | $37.00M derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-12-31 | $37.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $37.00M derived: sum of 2 quarters · filed 2026-03-26 | $37.00M derived: sum of 3 quarters · filed 2026-03-26 | $37.00M 10-K · filed 2026-03-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $0.00 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $0.00 10-Q · filed 2024-08-14 | ||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-15 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-04-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |